Method of treating rheumatoid arthritis with an anti-IL-6R antibody

US8192741B2 · kind B2 · utility

Assignee

• REGENERON PHARMACEUTICALS, INC. · US

Inventors

• Allen Radin · New York, US
• Sean Stevens · San Diego, US
• Tammy T. Huang · Goldens Bridge, US
• Joel H. Martin · Putnam Valley, US
• Jeanette L. Fairhurst · Thornwood, US
• Ashique Rafique · Yonkers, US
• Eric Smith · New York, US
• Kevin J. Pobursky · Beacon, US
• Nicholas J. Papadopoulos · Lagrangeville, US
• James P. Fandl · Lagrangeville, US
• Gang Chen · Sammamish, US
• Margaret Karow · Newbury Park, US

Key dates

• Filing date: Nov 1, 2011
• Grant date: Jun 5, 2012
• Expiry date: Nov 1, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.